Interim results from a recent Phase 2 clinical trial (ClinicalTrials.gov Identifier: NCT02217709) have shown that phenelzine, a non-selective MAO inhibitor, demonstrates efficacy as serum PSA declines in patients with biochemical recurrent castration-sensitive PC (17). Here, KLK3 is linked to pachyonychia congenita.